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Adjuvant therapy use among Appalachian breast
cancer survivors
Xi Tan, PhD, PharmD, Vincent D. Marshall, MS, Roger T. Anderson, PhD, Joseph Donohoe, PhD,
Fabian Camacho, MS, MA, and Rajesh Balkrishnan, PhD
Abstract: There is a paucity of literature systemically examining the
effects of access to cancer care resources on adjuvant endocrine
therapy (AET) use behaviors, especially in underserved regions such
as the Appalachian region in the United States, where gaps in
healthcare access are well documented. The objectives of this study
were to explore AET adherence and persistence in Appalachia,
delineate the effects of access to care cancer on adherence/persist-
ence, and evaluate the influences of adherence and persistence on
overall survival.
A retrospective cohort study from 2006 to 2008 was conducted
among female breast cancer survivors living in the Appalachian
counties of 4 states (PA, OH, KY, and NC). We linked cancer
registries to Medicare claims data and included patients with invasive,
nonmetastatic, hormone-receptor-positive breast cancer who received
guideline-recommended AET. Medication adherence was defined as
corresponding to a Medication Possession Ratio (MPR) 0.8 and
logistic regression was utilized to assess predictors of adherence.
Medication nonpersistence was defined as the discontinuation of
drugs after exceeding a 60-day medication gap, and multivariate
adjusted estimates of nonpersistence were obtained using the Cox
proportional hazards (PH) model.
About 31% of the total 428 patients were not adherent to AET, and
30% were not persistent over an average follow-up period of 421 days.
Tamoxifen, relative to aromatase inhibitors, was associated with
higher odds of adherence (odds ratio¼ 2.82, P< 0.001) and a lower
risk of nonpersistence (hazard ratio¼ 0.40, P< 0.001). Drug-related
side effects like pain may be an important factor leading to non-
adherence and early discontinuation. In addition, aromatase inhibitor
(AI) adherence and persistence were significantly influenced by out-
of-pocket drug costs, dual eligibility status, and coverage gaps.
Nonadherence to and nonpersistence with AET were associated with
higher risks of all-cause mortality.
Our findings of suboptimal AET adherence/persistence in
Appalachia as well as positive associations between AET adher-
ence/persistence and overall survival outcomes further underscore
the importance of ensuring appropriate AET use in this population
to reduce breast cancer mortality disparities. Our findings also
suggest that intervention strategies focusing on individualized
treatment and medication-related factors may improve adjuvant
treatment use.
(Medicine 94(26):e1071)
Abbreviations: AET = adjuvant endocrine therapy, AI = aromatase
inhibitor, ARC = Appalachian Regional Commission, ARF = Area
Resource File, CCI = Charlson Comorbidity Index, CDC = Centers
for Disease Control and Prevention, CMS = Centers for Medicare
and Medicaid services, CoC = Commission on Cancer, Cox PH =
Cox proportional hazards, HMO = Health Maintenance
Organization, HPSA = Health Professional Shortage Area, HR =
hormone-receptor, IRB = Institution Review Board, LIS = low-
income subsidies, MPR = Medication Possession Ratio, NCHS =
National Center for Health Statistics, NCI = National Cancer
Institute, NPI = National Provider Identifiers, OR = odds ratio, SD
= standard deviation, UPIN = Unique Physician Identification
Numbers.
INTRODUCTION
A djuvant endocrine therapy (AET) is a secondary preventiontherapy recommended for use among hormone-receptor
(HR) positive breast cancer survivors for a period of 5 to 10
years after surgery to reduce recurrence and improve survival.1–4
Additionally, patient adherence to and persistence with AET are
critical in maximizing treatment benefits; this has been identified
as a significant issue in clinical practice, with nonadherence and
nonpersistence rates as high as 59% and 73%, respectively.5,6 The
current literature showed a broad range of adherence and early
discontinuation rates ranging from 41% to 95.7% and 12% to
73%, respectively.5,6 Variations in adherence and persistence in
these studies may be attributable to heterogeneity in methodology
and study population. There is no gold standard method for
measuring adherence and persistence of AET in clinical practice,
nor is there a good biomarker available to measure the use of
tamoxifen or aromatase inhibitors (AIs).7 In the studies using
medical and pharmacy claims data, AET adherence was usually
defined as Medication Possession Ratio (MPR) 80%, while
nonpersistence/discontinuation was operationalized as the dis-
continuation of drugs after exceeding a permissible gap,8 which
ranged from 45 to 180 days depending on the study.5 The
discrepancies in persistence definitions may result in variations
in discontinuation rates. In addition, factors that were consistently
shown to be negatively associated with AET adherence or
persistence included extreme age, increasing out-of-pocket costs
of AET, seeing a general practitioner versus an oncologist during
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follow-up care, switching between drugs, and treatment-associ-
ated side effects.5,6,9
With the growing number of breast cancer survivors, breast
cancer care should not only provide active treatment but also
survivorship care such as posttreatment monitoring and risk-
reducing maintenance behaviors. However, there are very few
studies that systemically examine the effects of access to cancer
care resources on AET use behaviors, especially in underserved
regions where patients suffer from the deficiencies of access to
care, such as the Appalachian region. Additionally, in clinical
practice, the literature regarding direct therapeutic outcomes
associated with AET adherence and persistence remains under-
developed. Therefore, the objectives of this study were to
describe the prevalence of adherence to and persistence with
AET among Appalachian breast cancer survivors; assess the
effects of access to cancer care resources on AET adherence and
persistence; evaluate the influences of AET adherence and
persistence on survival after controlling for access factors.
METHODS
Study Design and Data Source
A retrospective cohort study from January 1, 2006 to
December 31, 2008 was conducted among female breast cancer
survivors living in the Appalachian counties of 4 states (PA, OH,
KY, and NC). The overall study design comprises 3 main
periods: the baseline period (1 year before the breast cancer
diagnosis), the diagnosis-to-AET period (the interval between
the diagnosis and the initiation of AET), and the follow-up
period (from the date of the first AET prescription filled until
death or the end of the observation period, December 31, 2008).
Multiple data sources were integrated for final analyses:
individual characteristics from cancer registries and Medicare
claims data; system-level characteristics from the Appalachian
Regional Commission (ARC) data reports, the 2010 U.S.
census, the Area Resource File (ARF), the National Center
for Health Statistics (NCHS), Centers for Disease Control and
Prevention (CDC), and the National Cancer Institute (NCI); and
provider/facility characteristics mainly from Medicare provider
files. First, we linked female breast cancer cases in the cancer
registries to Medicare claims data using patient identifiers
including name, social security number, gender, and birthdate.
Then, the cross-link was established between patient data and
system-level characteristics using county codes. The Unique
Physician Identification Numbers (UPIN) and National Provi-
der Identifiers (NPI) were utilized to link patient claims to
provider factors. The final dataset for statistical analyses had
completely deidentified information. Data use was approved by
the Centers for Medicare and Medicaid services (CMS) and
cancer registries, and the study was approved by the University
of Michigan’s Institution Review Board (IRB).
Study Population
We included adult women who were diagnosed with
confirmed stage I to III, HR positive, primary breast cancer
in 2007. Other inclusion criteria were continuous enrollment in
Medicare Parts A, B, and D, recorded history of primary breast
cancer treatment, eligibility for AET, and no AET use before the
primary breast cancer treatment. Patients who were enrolled in a
Health Maintenance Organization (HMO) or Medicare
Advantage Program or had conflicting information across data
sources were excluded from the study. Then we extracted a
subset group of subjects who received guideline-recommended
AET, which referred to the receipt of AET within 1 year
following diagnosis.10 To facilitate the measurement of medi-
cation adherence and persistence, we ensured that we followed
patients for a period of at least 6 months.
Outcome Measures
Adherence
We calculated AET adherence for each individual using
the MPR. It is defined as the ratio of the amount of days for
which the drug was dispensed divided by the number of days for
which drug was needed,11,12 which was determined in this study
using the following equation:13,14
Medication Possession Ratio ðMPRÞ
¼ number of days’ supply=ðnumber of follow-up days
 number of inpatient daysÞ
Additionally, the MPR was truncated between 0 and 1.2, as
well as dichotomized into adherence and nonadherence using
the conventional cutoff point of 0.8 (0MPR< 0.8: nonad-
herence; 0.8MPR 1.2: adherence). For those who switched
between tamoxifen and AI, we precluded any double-counting
of the days when the patient took both tamoxifen and AI.
Persistence
Medication persistence is defined as the act of complying
with a provider’s recommendations to use medications for a
prescribed length of time8 and is commonly operationalized in
retrospective claims data studies as the discontinuation of drugs
after exceeding a permissible gap.8,15 We defined AET non-
persistence as a minimum 60-day medication fill gap. Patients
who switched drugs within 60 days were still considered
persistent.
Survival
Overall survival was defined as the period from AET
initiation until death or the end of our observation.
Covariate Measures
We included the following access factors: county
economic status, county-level educational attainment, urban
or rural geographic residence, county-level infant and cancer
mortality rates, Health Professional Shortage Area (HPSA)
designation, age, marital status, state of residence, annual
median household income (at the census block group level),
dual Medicare and Medicaid eligibility indicator, average travel
time from the patient to the 3 closes mammography centers,
breast cancer stage, tumor size, lymph node status, patients’
comorbidities as measured by Charlson Comorbidity Index
(CCI),16 treatment facility’s Commission on Cancer (CoC)
accreditation status, number of beds, the provider’s specialty
and graduation year, the number of breast-cancer-related
follow-up visits (codes used are listed in Supplement Digit
Content 1), and timeliness of primary treatment initiation.
We also assessed the type of breast cancer treatments and
the type of AET (procedure and drug codes are listed in
Supplement Digit Content 2), as well as the following medi-
cation-related factors: the average monthly out-of-pocket drug
costs; whether patients reached the out-of-pocket threshold and
began to receive catastrophic coverage; the number of unique
prescription drugs coadministered during follow-up; the season
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at the initiation of AET: it was included in analyses because the
seasonal weather condition may have influences on travel and
transportation especially in a largely rural and mountainous
environment such as Appalachia, which in turn may affect
patient behaviors of picking up their drugs; AET-associated
side effects: we utilized proxy measures for AET-associated
side effects (eg, osteoporosis, hot flashes/night sweats, arthral-
gia) using the indicators of the use of evidence-based prescrip-
tion drugs for them. As per clinical recommendations for
managing AET-associated side effects,17–19 we created dummy
variables indicating whether or not patients used antidepressants
(fluoxetine, paroxetine, venlafaxine, citalopram, gabapentin),
bisphosphonates (zoledronic acid, alendronate, risedronate),
and pain medications (opioids, gabapentin, pregabalin) during
follow-up.
Statistical Analyses
We conducted descriptive analyses by using means for
continuous variables and frequencies and percentages for binary
and categorical variables. Preliminary bivariate association
analyses were conducted to find potential predictors of adher-
ence, persistence, and survival. We conducted 2-tailed t-tests for
continuous predictors of adherence and Chi-square tests for
binary and categorical predictors of adherence. We used
Kaplan–Meier survival curves and log-rank tests to assess
the associations between each binary/categorical variable and
persistence or survival time, as well as univariate Cox regression
analyses to evaluate the relationships between each continuous
variable and persistence or survival time.
Multivariate logistic regression was used to assess the
relationship between access to cancer care and AET adherence.
For the sake of parsimony, we incorporated potentially signifi-
cant predictors with a P-value<0.25 in the bivariate association
analyses into the final multivariate logistic model with a robust
standard error.
We obtained multivariate adjusted estimates of nonpersis-
tence (discontinuation) using the Cox proportional hazards (PH)
model. We included in the final model only those predictors for
which P< 0.25 in the bivariate association analyses. We utilized
the Efron method to handle ties. We checked the proportional
hazard assumption of the variables by using the Schoenfeld and
scaled Schoenfeld residuals. If a variable did not meet the
assumption, we estimated a stratified Cox model based on the
variable.20 We also utilized Cox PH models to assess whether
AET adherence and persistence influence all-cause mortality.
Sensitivity analyses were also conducted by redefining
AET adherence and persistence as MPR cutoff points ranging
from 0.6 to 0.9 and a 90-day medication fill gap, respectively.
The statistical significance level was set to P< 0.05. We used R
3.0.2 (R Foundation for Statistical Computing, Vienna, Austria)
for general data management, ArcGIS 10.1 (ESRI, Redlands,
CA) for geo-related data management, and Stata 13 (StataCorp
LP, College Station, TX) for analyses.
RESULTS
Our final study sample consisted of 428 Medicare-enrolled
women with breast cancer living in the 125 Appalachian
counties of 4 states (KY, NC, OH, and PA) who initiated
AET within 1 year after the diagnosis. Eligible patients were
followed for a period of 181 to 706 days, with an average of 421
days. The mean MPR was 0.83 (standard deviation [SD]¼ 0.24,
range¼ [0.06, 1.2]), and approximately 69.4% were adherent to
AET. The average AET persistence time was 347.6 days, and
the early discontinuation rate was about 30.1%. Table 1
describes county-level characteristics. The results confirmed
the deficiencies in access to care in Appalachia including
economically distressed or at risk populations (43.2%), largely
rural environments (67.2%), and healthcare professional
shortages (88%), as well as low community educational levels
and high infant and cancer mortality rates. The percentages of
less than high school graduate (18.8%) and at least a bachelor’s
degree among persons aged 25 and over (15.9%) and living in
these Appalachian counties were worse than national averages
(15% and 27.9%, respectively). The mean infant mortality rate
(7.2 per 1000 births) and cancer mortality rate (197.7 per
100,000 population) of these Appalachian counties were also
higher than the national average estimates (6.75 per 1000 births
and 173.8 per 100,000 population, respectively). Bivariate
association analyses showed that adherent and persistent
patients were more likely to live in counties with a lower infant
mortality rate (P¼ 0.05 and P¼ 0.24, respectively). But, over-
all, we did not find bivariate associations with strong signifi-
cance between county-level factors and adherence/persistence.
Table 2 presents the descriptive analysis results of individual,
facility/provider, and medication-related characteristics. During
the follow-up period, eligible patients had 2.25 breast-cancer-
related follow-up visits, on average. An average of approxi-
mately 11.6 prescription drugs was coadministered to patients.
Approximately 26.4% of the population reached the cata-
strophic coverage threshold. Moreover, the use rates of anti-
depressants, bisphosphonates, and pain medications that can
treat AET-associated side effects were about 9.1%, 21.5%, and
TABLE 1. Descriptive Statistics of System-Level Characteristics
(by County) (N¼125)
Variables Mean (SD)
Percentage of less than high school graduate
among persons aged 25 and over (%)
18.8 (7.7)
Percentage of at least a bachelor’s degree
among persons aged 25 and over (%)
15.9 (6.4)
Infant death rate per 1000 births 7.2 (0.85)
Annual age-adjusted, cancer-related death
rate per 100,000 population
197.7 (28.8)
Frequency (%)
ARC’s county economic status
Distressed 30 (24.0%)
At risk 24 (19.2%)
Others 71 (56.8%)
Annual median household income (US dollar), quartile

Low ($9768–$31,408.5) 107 (25%)
Second ($31,408.5–$41,552) 107 (25%)
Third ($41,552–$51,577.5) 107 (25%)




Health Professional Shortage Area (HPSA) designation
Whole county in HPSA 40 (32.0%)
Part county in HPSA 70 (56.0%)
Not in HPSA 15 (12.0%)
ARC¼Appalachian Region Commission, SD¼ standard deviation.
At the census block group level.
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10%, respectively. Dual eligibility status, catastrophic cover-
age, lymph node status, and use of pain medications had
significant bivariate associations with AET adherence and
persistence (P< 0.05).
Tables 3 and 4 show factors significantly associated with
AET adherence and discontinuation: AET drug class, cata-
strophic coverage, and use of pain medications. Please note
that because dual eligibility status and provider specialty did not
meet the proportional hazard assumption, our final Cox PH
model of AET discontinuation was stratified by these 2 vari-
ables. Patients receiving catastrophic coverage benefits had
about 3-fold odds of adhering to AET (odds ratio
[OR]¼ 3.25, P¼ 0.001) and a 44% lower risk of discontinuing
AET (hazard ratio¼ 0.56, P¼ 0.03). Coadministration of pain
medications was associated with 68% reduced odds of adher-
ence to AET (OR¼ 0.32, P¼ 0.003) and an estimated 2.5 times
increased risk of AET nonpersistence (hazard ratio¼ 2.47,
P¼ 0.002). Tamoxifen was associated with greater likelihood
of adherence (OR¼ 2.82, P¼ 0.003) and persistence (hazard
ratio¼ 0.40, P¼ 0.002) than AIs.
We next stratified our population into those who took
tamoxifen and those who took AIs and reestimated the models.
We found that increased out-of-pocket prescription drug costs
were associated with reduced likelihood of adherence in the AI
group (OR¼ 0.99, P¼ 0.008), but the results were not signifi-
cant in the tamoxifen group. In terms of side effects, we found
that using pain medications was significantly associated with
poor adherence (OR¼ 0.41, P¼ 0.03) and persistence (hazard
ratio¼ 1.94, P¼ 0.05) to AI but not to tamoxifen. We then
TABLE 2. Descriptive Statistics of Individual, Facility/Provider,
and Medication-Related Characteristics (N¼428)
Variables Mean (SD)
Average travel time to the 3 closest
mammography centers (minute)
15.9 (10.2)
Baseline Charlson Comorbidity Index (CCI) 0.63 (0.95)
Baseline number of hospitalizations 0.38 (0.97)
No. of breast-cancer-related follow-up visits 2.25 (2.44)
Average monthly out-of-pocket costs (US dollar) 50.0 (64.2)
No. of unique prescription drugs coadministered 11.6 (6.24)















Dual Medicare and Medicaid eligibility status
Dual eligible 121 (28.3%)





Stage I 239 (55.8%)
Stage II 149 (34.8%)
Stage III 40 (9.4%)
Tumor size
<1 cm 84 (19.6%)
1–2 cm 215 (50.2%)





















Before 1980 163 (38.1%)
1980s 186 (43.5%)
After 1989 79 (18.5%)
Breast cancer surgery type
Mastectomy 166 (38.8%)
Breast conserving surgery (BCS)þ radiation 139 (32.5%)




Timeliness of primary treatment initiation
Timely treatment (surgery within 60 days) 398 (93.0%)







Use of pain medications
Yes 43 (10.0%)
No 385 (90.0%)





Note: The percentages of some variables may not add up to 100% due
to rounding errors.
AET¼ adjuvant endocrine therapy, SD¼ standard deviation.
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stratified the population by dual-eligible enrollees versus Med-
icare only enrollees. Those dual-eligible enrollees who quali-
fied for low-income subsidies (LIS) did not experience the drug
coverage gap experienced by Medicare-only enrollees; we did
not find that receiving catastrophic coverage benefits signifi-
cantly affected AET adherence or persistence among these dual-
eligible enrollees. For Medicare-only enrollees, however,
receiving catastrophic coverage significantly improved AI
adherence (OR¼ 6.20, P¼ 0.001) and persistence (hazard
ratio¼ 0.31, P¼ 0.01) but did not have significant impacts
on tamoxifen use. The results of using differing definitions
of adherence and persistence in our sensitivity analyses showed
that AET drug class and catastrophic coverage were robust
predictors of AET adherence while AET drug class and the use
of pain medication were stable predictors of AET persistence.
During the study period, all-cause death occurred in 15
patients (3.5% of our sample). The Kaplan–Meier survival
curves by AET medication adherence and persistence (shown
in Figures 1 and 2) showed that patients who were not adherent
to or persistent with AET had a higher risk of death, both with
TABLE 3. Predictors of Adherence to Adjuvant Endocrine Therapy (AET) Among Appalachian Women With Breast Cancer:
Multivariate Logistic Regression (N¼428)
Variable Adherence to AET,
Odds Ratio (95% CI)
P-Value
Percentage of at least a bachelor’s degree among persons aged 25 and over (%) 0.997 (0.957, 1.039) 0.89
Infant death rate per 1000 births 1.16 (0.66, 2.04) 0.60
Annual age-adjusted, cancer-related death rate per 100,000 population 1.01 (0.99, 1.02) 0.30
Baseline Charlson Comorbidity Index (CCI) 1.08 (0.83, 1.40) 0.56
Average monthly out-of-pocket costs (US dollar) 0.997 (0.993, 1.001) 0.09
Health Professional Shortage Area (HPSA) designation
Whole county in HPSA Reference Reference
Part county in HPSA 1.19 (0.49, 2.91) 0.70
Not in HPSA 1.26 (0.45, 3.55) 0.66
State
KY 0.39 (0.14, 1.13) 0.08
NC 0.43 (0.07, 2.60) 0.36
OH 0.66 (0.30, 1.42) 0.29
PA Reference Reference
Dual Medicare and Medicaid eligibility status
Dual-eligible 1.26 (0.59, 2.68) 0.56
Medicare-only Reference Reference
Catastrophic coverage indicator




Positive 1.51 (0.86, 2.66) 0.16
Commission on Cancer (CoC) accreditation
Yes 0.89 (0.53, 1.50) 0.66
No Reference Reference
Provider specialty
Oncology 1.25 (0.73, 2.16) 0.42
General practitioner Reference Reference
Other 0.54 (0.26, 1.10) 0.09
Breast cancer surgery type
Mastectomy Reference Reference
Breast conserving surgery (BCS)þ radiation 0.74 (0.40, 1.35) 0.32
BCS, no radiation 0.66 (0.36, 1.21) 0.18
Use of bisphosphonates
Yes 1.39 (0.78, 2.46) 0.26
No Reference Reference
Use of pain medications
Yes 0.32 (0.15, 0.67) 0.003
No Reference Reference
AET drug class
Tamoxifen 2.82 (1.42, 5.64) 0.003
Aromatase inhibitor (AI) Reference Reference
Switching between 2 drug classes 2.20 (0.85, 5.66) 0.10
P< 0.05 is considered to be statistical significant.
AET¼ adjuvant endocrine therapy, 95% CI¼ 95% confidence interval.
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significant log-rank test results (P¼ 0.04 and 0.01, respect-
ively). Multivariate adjusted Cox PH models also supported
these findings (shown in Tables 5 and 6). Eligible breast cancer
survivors who were not adherent to or persistent with AET had
greatly higher risks of death than those who were adherent or
persistent (both P¼ 0.003), after controlling for other factors.
Additionally, other significant factors associated with increased
risk of all-cause death were increased age and being treated in
non-CoC accredited facilities. The conclusions did not differ if
we changed the definitions of adherence and persistence.
DISCUSSION
Our study is among the first to delineate the manner in
which multidimensional determinants of access to cancer care
affect patient medication use behaviors, specifically, adherence
TABLE 4. Factors Associated With Discontinuation of Adjuvant Endocrine Therapy (AET) Among Appalachian Women With Breast
Cancer: Cox Proportional Hazards (PH) Model, Stratified by the Provider’s Specialty and the Patient’s Dual Eligibility Status
(N¼428)
Variable AET Discontinuation,
Hazard Ratio (95% CI)
P-Value
Percentage of at least a bachelor’s degree among persons aged 25 and over (%) 0.99 (0.96, 1.02) 0.64
Infant death rate per 1000 births 1.08 (0.90, 1.31) 0.40
Annual age-adjusted, cancer-related death rate per 100,000 population 1.00 (0.99, 1.01) 0.81
Baseline Charlson Comorbidity Index (CCI) 0.96 (0.77, 1.19) 0.71
Age at diagnosis
<65 0.47 (0.16, 1.36) 0.16
65–74 Reference Reference
75–84 1.10 (0.73, 1.66) 0.65
85 1.17 (0.63, 2.19) 0.62
Marital status
Married 1.13 (0.76, 1.69) 0.54
Not married Reference Reference
Annual median household income (US dollar), quartile
Low ($9768–$31,408.5) Reference Reference
Second ($31,408.5–$41,552) 1.26 (0.73, 2.17) 0.40
Third ($41,552–$51,577.5) 1.06 (0.61, 1.85) 0.84
High ($51,577.5–$15,0625) 1.25 (0.71, 2.20) 0.44
Catastrophic coverage indicator




Positive 0.69 (0.43, 1.10) 0.12
Commission on Cancer (CoC) accreditation
Yes 1.22 (0.76, 1.94) 0.41
No Reference Reference
Facility beds
<100 beds 1.20 (0.65, 2.21) 0.57
100–199 beds 0.75 (0.44, 1.28) 0.29
200 beds Reference Reference
Breast cancer surgery type
Mastectomy Reference Reference
Breast conserving surgery (BCS)þ radiation 1.14 (0.70, 1.86) 0.60
BCS, no radiation 1.50 (0.94, 2.40) 0.09
Use of bisphosphonates
Yes 0.75 (0.46, 1.20) 0.23
No Reference Reference
Use of pain medications
Yes 2.47 (1.41, 4.33) 0.002
No Reference Reference
AET drug class
Tamoxifen 0.40 (0.22, 0.71) 0.002
Aromatase inhibitor (AI) Reference Reference
Switching between 2 drug classes 0.86 (0.41, 1.80) 0.70
P< 0.05 is considered to be statistical significant.
AET¼ adjuvant endocrine therapy, 95% CI¼ 95% confidence interval.
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to and persistence with adjuvant treatments, in Appalachia. The
AET adherence rate and early discontinuation rate in the first
2 years among Appalachian women with invasive, nonmetastatic,
HR-positive breast cancer were 69% and 30%, respectively. We
found that adherence rates in previous studies using US pharmacy
claims data were in the range of 70% to 80%,21–24 and the
discontinuation rates were fairly consistent at around 20%.22,25–27
Overall, AET adherence and persistence seems to be lower in
Appalachia compared to the rest of the United States.
Our findings suggested that adherence to and persistence
with AET were primarily related to the medication-related
factors. Tamoxifen was associated with better medication use
outcomes than AIs, which may be attributable to different
adverse effect profiles and drug costs. The use of pain medi-
cations, presumably to treat AI-related musculoskeletal pain,
was significantly associated with poor adherence and persist-
ence, which may partially explain the worse medication use
outcomes associated with AIs. Other research showed that
AET-induced side effects like musculoskeletal pain may
increase physical burden on patients, cause misbeliefs about
AET use, and adversely affect patients’ intentions to adhere to
the medication.28,29 Our study supports this conclusion and
highlights the need to develop interventions that focus on
individualized side-effect management and better patient edu-
cation about AET use.
In addition, tamoxifen generally involves lower costs to
both patients and third-party payers than AIs, so it may be
associated with reduced financial burden in the long run. We
found a negative relationship between out-of-pocket drug costs
and adherence among patients who used AIs only (OR¼ 0.99,
P¼ 0.008) but did not find a significant relationship among
those who used tamoxifen only. The relationship may be
influenced by several factors: type of Medicare healthcare plan,
dual eligibility status that can determine the qualification for
LIS, whether patients enter the coverage gap, and whether
patients receive catastrophic coverage benefits beyond the
out-of-pocket threshold. Riley et al21 found that adherence
rates did not differ much between patients with and without
LIS in the tamoxifen group but adherence to AIs was signifi-
cantly improved if patients received LIS. In the present study,
however, we did not establish a significant interaction between
AET drug class and dual eligibility status to predict adherence
or persistence. Previous research found that AET adherence
declined when Medicare-only patients without LIS entered in
the coverage gap compared to precoverage gap21; our study
further found that AI adherence and persistence improved
significantly after these patients got out of the coverage gap
and received catastrophic coverage benefits, but we found no
significant changes in tamoxifen adherence and persistence in
the same circumstances.
Even with the constraints of small sample size and short
follow-up time, we found significant positive relationships
between nonadherence/nonpersistence to AET and all-cause
mortality. Hershman et al30 found that nonpersistence and
nonadherence to AET were significantly associated with
increased hazard of all-cause death by 26% and 49%, respect-
ively. Similarly, McCowan et al31 identified a 10% increase in
the hazard of all-cause mortality among those who were not
adherent to tamoxifen, compared to those who were adherent, as
well as a significantly lower risk of death associated with use of
tamoxifen over a long duration. In addition, we found in the
Kaplan–Meier curves that 480 to 580 days showed the largest
survival difference (300–400 days in the figures since the start
time of the figures was 180 days following the initiation of
AET). As per the Kaplan–Meier curve in the Hershman et al30
that assessed 10-year survival difference, the effect of adher-
ence to AET on survival became prominent since 1.5 to 2 years
after initiation. The smaller difference in the tails of our figures
may be attributable to the very limited number of subjects left in
both arms because 90% of our study population had less than
581-day follow-up time. The effects of adherence/persistent
with AET would be even clearer if we had larger sample size
and longer follow-up that can cover the whole clinical course of
AET. Nevertheless, our findings plus previous evidence may
imply the importance of ensuring appropriate AET use in the
pursuit of additional gains in survival. It is also noteworthy that
AET adherence and persistence may have different influences
on survival. By definition, AET persistence emphasizes more
on the recommended length of time, which was determined by
clinical evidence of benefits in breast cancer outcomes.32,33
AET adherence focuses on whether patients can use AET
everyday as recommended to keep a steady drug level that is
FIGURE 1. Kaplan–Meier curves of overall survival by adjuvant
endocrine therapy (AET) adherence. Patients who were not adher-
ent to AET (solid line) had a higher risk of death than those who
were adherent (dash line), and the log-rank test showed signifi-
cant result (P¼0.04). Note: The start time of survival analysis was
180 days after the initiation of AET because our study design only
included patients who were alive for at least 180 days after the
initiation of AET.
FIGURE 2. Kaplan–Meier curves of overall survival by adjuvant
endocrine therapy (AET) persistence. Patients who were not per-
sistent with AET (solid line) had a higher risk of death than those
who were persistent (dash line), and the log-rank test showed
significant result (P¼0.01). Note: The start time of survival
analysis was 180 days after the initiation of AET because our study
design only included patients who were alive for at least 180 days
after the initiation of AET.
Medicine  Volume 94, Number 26, July 2015 Medication Use in Appalachian Breast Cancer Survivors
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com | 7
warranted to maximize the drug effectiveness and improve
clinical outcomes. However, again, long follow-up time that
can cover the whole recommended clinical course of AET may
be needed to differentiate the effects of AET adherence and
persistence on breast cancer outcomes.
This study had several limitations. First, the relatively
short length of the follow-up period and small sample size
limited our ability to conduct further analyses such as breast-
cancer-related survival or the changes in adherence and per-
sistence over the whole recommended clinical course of AET
(5–10 years). Second, we did not include some detailed infor-
mation and potential predictors, such as accurate drug indica-
tions, prescribers’ characteristics, pharmacy type, and patient
attitudes and beliefs about long-term AET use. Third, when
using administrative claims data to assess medication adher-
ence/persistence, we assumed that the claims were billed in an
accurate and timely manner, AET was obtained only through
Medicare Part D, and the medication was actually taken by the
patients. These assumptions may not always be true under all
circumstances, which may cause measurement errors. For
example, patients might obtain AET from other sources than
through Medicare Part D, which may not be captured in our
dataset especially when in the coverage gap. Dually eligible
patients may receive additional benefits from their Medicaid
programs to help with their out-of-pocket money, which were
not considered in our calculation of out-of-pocket drug costs.
Finally, the generalization of results may be limited to our target
population that was Medicare enrollees with breast cancer who
lived in Appalachia and were first-time users of tamoxifen and
AIs. We did not study ovarian suppression/ablation, or the use
of tamoxifen or AIs as primary treatments or neoadjuvant
therapy for breast cancer, or AET use in a general breast cancer
patient population, which is typically younger than our
study population.
CONCLUSION
AET adherence and persistence are suboptimal in Appa-
lachia. They differ between drug classes possibly as a result of
distinct adverse effect profiles and differences in patient afford-
ability stemming from drug costs and health plan benefits.
Additionally, we confirm the substantial benefits of adherence
to and persistence with AET in achieving the advancement of
overall survival. Therefore, this study suggests the value of
TABLE 5. The Association Between Adjuvant Endocrine Therapy (AET) Nonadherence and All-Cause Mortality Among Appa-
lachian Women With Invasive, Nonmetastatic, and Hormone Receptor Positive Breast Cancer, Using Cox Proportional Hazards
(PH) Model (N¼428)
Variable All-Cause Mortality, Hazard Ratio (95% CI) P-Value
Adherence to AET
Yes Reference Reference
No 9.15 (2.11, 39.62) 0.003
Age at diagnosis (year) 1.14 (1.04, 1.25) 0.004
Marital status
Married 1.75 (0.26, 11.57) 0.56
Not married Reference Reference
Dual Medicare and Medicaid eligibility status
Dual eligible 3.07 (0.76, 12.41) 0.12
Medicare only Reference Reference
Stage
Stage I Reference Reference
Stage II 1.46 (0.20, 10.40) 0.71
Stage III 1.25 (0.10, 16.05) 0.86
Tumor size
<1 cm Reference Reference
1–2 cm 0.20 (0.02, 1.57) 0.12
>2 cm 0.46 (0.04, 4.60) 0.51
Commission on Cancer (CoC) accreditation
Yes 0.12 (0.02, 0.72) 0.02
No Reference Reference
Facility beds
<100 beds 1.54 (0.29, 8.08) 0.61
100–199 beds 3.07 (0.56, 16.64) 0.19
200 beds Reference Reference
Breast cancer surgery type
Mastectomy Reference Reference
Breast conserving surgery (BCS) 0.47 (0.12, 1.92) 0.30
Baseline number of hospitalizations 0.99 (0.65, 1.49) 0.95
No. of breast-cancer-related follow-up visits 0.56 (0.30, 1.07) 0.08
No. of unique prescription drugs coadministered 0.97 (0.88, 1.07) 0.60
P< 0.05 is considered to be statistical significant.
AET¼ adjuvant endocrine therapy, 95% CI¼ 95% confidence interval.
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adding a component focusing on medication management
related to AET use to current cancer care models in Appalachia
with the ultimate goal of reducing breast cancer mortality
disparities.
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